Damora Therapeutics, Inc.
NASDAQ:DMRABiotechnology
+$0.07 today
- Market cap
- $1.42B
- Beta
- 1.48
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$177.15
Volume 0.58M
Average 0.33M
DMRA Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Damora Therapeutics, Inc.NASDAQ: DMRA
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses grows, but more slowly than its trailing trend
Q1 FY2026 operating expenses of $30.74M rose 1082.9% year over year, behind the +1655.8% change in trailing-twelve-month operating expenses. Sequentially, it fell 84.8% from the prior quarter. Over 3 fiscal years it compounded at +51.4% a year.
Context
- Operating expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +1082.9% toward the trailing-twelve-month pace of +1655.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 210.87M USD
- Year-over-year change
- +1161.5%
- 4-year CAGR
- +42.1%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 210.87M | +1161.5% |
| FY2024 | 2024-12-31 | 16.72M | -53.1% |
| FY2023 | 2023-12-31 | 35.63M | -41.3% |
| FY2022 | 2022-12-31 | 60.72M | +17.2% |
| FY2021 | 2021-12-31 | 51.79M | — |
Operating Expenses vs competitors
How DMRA compares with its peers on the latest reported figures
- DMRA's LTM Mar 2026 operating expenses of $239.02M is the 4th highest of the 9 companies compared; the peer median is $205.96M.
- Its year-over-year change of +1655.8% is the highest of 7, against a peer median of +10.3%.
- Over three fiscal years its annual growth of +51.4% compares with a peer median of +9.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $3.55B | +8.1% | +9.7% | 61.0% | |
| LTM Jun 2026 | $2.51B | — | -36.0% | 60.7% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $265.73M | +30.5% | +70.7% | — |
DMRADamora Therapeutics, Inc. | LTM Mar 2026 | $239.02M | +1655.8% | +51.4% | — |
| LTM Mar 2026 | $207.18M | -16.5% | +18.7% | 105.6% | |
| LTM Mar 2026 | $204.75M | +13.6% | -6.4% | 1131.6% | |
| LTM Mar 2026 | $155.37M | +12.5% | -5.0% | 51.8% | |
| LTM Mar 2026 | $142.36M | -36.6% | +14.4% | 429.0% | |
COAGHemab Therapeutics Holdings, Inc. Common Stock | FY2025 | $70.12M | — | — | — |
| Peer median (excluding DMRA) | $205.96M | +10.3% | +9.7% | 83.3% | |
Competitors are the stored peer set for DMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 441K | 490K | 830K | 181K | 0 |
| Gross Profit | (441K) | (490K) | (830K) | (181K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 38.49M | 48.21M | 23.77M | 6.4M | 201.19M |
| Selling, General & Admin | 13.3M | 12.51M | 11.86M | 10.32M | 9.69M |
| Operating Expenses | 51.79M | 60.72M | 35.63M | 16.72M | 210.87M |
| Depreciation & Amortization | 441K | 490K | 830K | 181K | 34K |
| EBITDA | (51.31M) | (61.13M) | (37.52M) | (21.22M) | (209.76M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (52.23M) | (61.21M) | (36.46M) | (16.9M) | (210.87M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 156K | 722K | 1.69M | 844K | 1.17M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 475K | (417K) | (1.89M) | (4.5M) | 1.08M |
| Income Before Tax | (51.75M) | (61.62M) | (38.35M) | (21.4M) | (209.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 41K | 50K |
| Net Income | (51.75M) | (61.62M) | (38.35M) | (21.44M) | (209.84M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (51.22) | (60.63) | (36.08) | (18.53) | (158.13) |
| EPS (Diluted) | (51.22) | (60.63) | (36.08) | (18.53) | (158.13) |
| Weighted Avg Shares | 1.01M | 1.02M | 1.06M | 1.16M | 1.33M |
| Weighted Avg Shares (Diluted) | 1.01M | 1.02M | 1.06M | 1.16M | 1.33M |
Damora Therapeutics, Inc.
NASDAQ:DMRA
Intrinsic Alpha fair value
Locked
Current Price
$22.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.